Clinics in Chest Medicine

Our medical research library holds 9 studies published in Clinics in Chest Medicine (1998–2021). Each entry links to the study's record on PubMed and, where there is one, to the publisher's page and a free full text. 8 have an abstract, the authors' own summary as PubMed records it: open "Abstract" to read it.

About the journal

• Publisher: Elsevier Health Sciences Division
• Published: 1980 to the present, United States
• Language: English
• ISSN: 0272-5231 (print), 1557-8216 (electronic)
• Its record in the NLM Catalog

2020s

• Malignant Pleural Mesothelioma: Updates for Respiratory Physicians. C. Sidhu, A. Louw, Y.C. Gary Lee. 2021;42(4):697-710. Review PubMed · Publisher

2010s

• Intracavitary Therapeutics for Pleural Malignancies. V. Murthy, K. Mangalick, D.H. Sterman. 2018;39(1):195-209. Review PubMed · Publisher

  Abstract

  Pleural malignancies remain a serious therapeutic challenge, and are frequently refractory to standard treatment; however, they have the advantage of occurring in an enclosed cavity readily accessible for examination, biopsy, and serial sampling. Novel therapeutics can be administered via intracavitary delivery to maximize efficacy by targeting the site of involvement and potentially mitigating the adverse effects of systemic therapies. The easy accessibility of the pleural space lends itself well to repeated sampling and analysis to determine efficacy and toxicity of a given treatment paradigm. These factors support the rationale for delivery of novel therapeutics directly into the pleural space.

  Copyright © 2017 Elsevier Inc. All rights reserved.

• Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies. A.R. Haas, D.H. Sterman. 2013;34(1):99-111. Review PubMed · Publisher · Free full text

  Abstract

  There is evidence that improved treatments of malignant pleural mesothelioma are increasing the quality and quantity of life for patients with mesothelioma. Multimodality treatment programs that combine maximal surgical cytoreduction with novel forms of radiation therapy and more effective chemotherapy combinations may offer significant increases in survival for certain subgroups of patients with mesothelioma. Lung-sparing surgery may allow improvements in pulmonary function after surgery-based multimodality therapy, and potential longer overall survival than that seen with extrapleural pneumonectomy. Experimental treatments provide hope for all patients with mesothelioma, and in the future may be combined with standard therapy in multimodality protocols.

  Copyright © 2013 Elsevier Inc. All rights reserved.

• Rare pleural tumors. C.T. Erb, K.M. Johnson, A.W. Kim. 2013;34(1):113-36. Review PubMed · Publisher

  Abstract

  Primary pleural tumors other than mesothelioma account for fewer than 1% of all lung cancers, and consequently they pose diagnostic and management challenges. Their treatment must be targeted toward the specific tumor type and is often quite different from the treatment for mesothelioma or metastases. Despite the best efforts at diagnosing and treating these tumors, the prognosis associated with some of the benign and many of the malignant variants of these tumors remains poor. In this review, we describe the radiologic and pathologic features of the less common primary pleural tumors and propose a diagnostic approach to their evaluation.

  Copyright © 2013 Elsevier Inc. All rights reserved.

• The classic pneumoconioses: new epidemiological and laboratory observations. A.S. Laney, D.N. Weissman. 2012;33(4):745-58. Review PubMed · Publisher

  Abstract

  The purpose of this article is to provide an update on selected issues of current interest and recent developments related to 3 types of inorganic mineral dust exposures causing classic forms of pneumoconiosis: coal mine dust, crystalline silica, and asbestos. Common themes include new imaging modalities, emerging exposures, and evolving appreciation of additional adverse health effects associated with exposure to these inorganic mineral dusts.

  Published by Elsevier Inc.

• Gene therapy for lung neoplasms. A. Vachani, E. Moon, E. Wakeam, et al. 2011;32(4):865-85. Review PubMed · Publisher · Free full text

  Abstract

  Both advanced-stage lung cancer and malignant pleural mesothelioma are associated with a poor prognosis. Advances in treatment regimens for both diseases have had only a modest effect on their progressive course. Gene therapy for thoracic malignancies represents a novel therapeutic approach and has been evaluated in several clinical trials. Strategies have included induction of apoptosis, tumor suppressor gene replacement, suicide gene expression, cytokine-based therapy, various vaccination approaches, and adoptive transfer of modified immune cells. This review considers the clinical results, limitations, and future directions of gene therapy trials for thoracic malignancies.

  Copyright © 2011 Elsevier Inc. All rights reserved.

2000s

• Smoking and the molecular epidemiology of lung cancer. D.C. Christiani. 2000;21(1):87-93, viii. Review PubMed · Publisher

  Abstract

  Lung carcinogenesis in humans requires exposure to environmental agents, including the inhalation of tobacco smoke, radioactive compounds, asbestos, heavy metals, and petrochemicals. Tobacco smoking is the risk factor with the highest attributable lung cancer risk worldwide. This article discusses occupational carcinogen exposure and exposure from tobacco use, and the lung-cancer risk associated with these types of exposure.

1990s

• Asbestos-induced pleural disease. S.L. Nishimura, V.C. Broaddus. 1998;19(2):311-29. Review PubMed · Publisher

  Abstract

  Asbestos-induced pleural disease has become the most common manifestation of asbestos exposure. Asbestos has an unusual affinity for the pleural space and leads to plaques, benign effusions, fibrosis, and malignant mesothelioma. The explanation for its affinity for the pleura may lie in part with new evidence showing that asbestos fibers can accumulate in certain regions of the parietal pleura at higher concentrations than in the lung. With the control of industrial exposures to asbestos, the incidence of this disease should decrease, with the incidence of mesothelioma peaking in the years 2000 to 2020. Nonetheless, the toxic features of asbestos including shape, chemical composition, and surface characteristics should be understood to avoid toxicity in fibers used to replace asbestos and to know the risks of low level exposures from asbestos currently in our environment.

• CT and MR in pleural disease. T.C. McLoud. 1998;19(2):261-76. Review PubMed · Publisher

  Abstract

  A number of different imaging modalities can be used in the assessment of pleural disease. Although ultrasound has been the more traditional method, CT has found increasing utility for the assessment of the empyema and loculated pleural fluid collections prior to drainage and the evaluation of benign and malignant pleural tumors. MRI has a limited but important role particularly in the evaluation of focal pleural tumors such as lipomas and in determining the extent of malignant mesothelioma prior to therapy.

Browse every journal in the library or the library by type of article, or return to medical research.